/
Nephrology
Chronic Kidney Disease
108
Pipeline Programs↗
187
Active Trials↗
100
Companies Involved↗
Chronic Kidney Disease is a highly competitive landscape with 108 programs across 100 companies. The most active players are AstraZeneca, Novo Nordisk, Bayer. 20 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical64
Phase 18
Phase 216
Phase 320
Approved
No programs
Analysis
Modality Breakdown
91%
Small molecule
92 of 101 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 101 classified programs, each share of the total. Modality classified for 99% of 108 pipeline programs.
Analysis
Trial Status
771
clinical trials
Completed425 · 55%
Recruiting95 · 12%
Unknown status62 · 8%
Terminated61 · 8%
Not yet recruiting54 · 7%
Active, not recruiting35 · 5%
Other39 · 5%
Clinical Trials
Trial Activity
771 trials
Physical Exercise in Hemodialysis Patients in End Stage Kidney Disease
Recruiting·—·Preclinical·NCT07820514·312 enrolled
Page 1 of 52
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)